PRAXIS PRECISION MEDICINES I
PRAXNASDAQ🏆 #690 by market capUS Equity
$542.22▲ $30.53 (+5.63%)
🌙 After hours$370.68▼ 31.64%Simulated price1h—
24h▲ 5.6%
7d▲ 69.9%
14d▲ 86.3%
30d▲ 72.4%
1y▲ 1019.4%
🏦Market Cap
$10.25B
Mid Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
1197.9x
Expensive
Otter Score
62
Fair
Trading Snapshot
- Day Range
- $536.46 – $548.26
- 52-Week Range
- $37.19 – $382.54
- Volume
- $2.64B
- Avg Volume
- $3.10B
- Shares Outstanding
- 27.9M
- Next Earnings
- Sep 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 1197.9x
- EPS (TTM)
- $-13.37
- Dividend Yield
- —
Why Investors Own PRAX
- ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 80% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$9M▲ +17.8% YoY
Gross Margin (TTM)
79.8%▲ +3.7% YoY
Operating Income (TTM)
$3M▲ +17.8% YoY
Free Cash Flow (TTM)
$2M▲ +17.8% YoY
About PRAXIS PRECISION MEDICINES I
A company profile for PRAXIS PRECISION MEDICINES I isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
62/100
Analyst Price Target
ⓘAverage Target
$585.79
▲ +8.0% Upside
High Target$651.97
Low Target$531.61
Based on 20 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
PRAXIS PRECISION MEDICINES I tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift PRAX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
PRAXIS PRECISION MEDICINES I announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.